Management of cancer treatment-induced bone loss

Nature Reviews Rheumatology

Volumn 9, Issue 6, 2013, Pages 365-374

  Coleman, Robert E ^a   Rathbone, Emma ^b   Brown, Janet E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENOSUMAB; EXEMESTANE; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; IBANDRONIC ACID; METHOTREXATE; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE TURNOVER; BREAST CANCER; CANCER SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FRACTURE; GYNECOLOGIC DISEASE; HUMAN; LIFESTYLE MODIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SPINE FRACTURE; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84878546621     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.36     Document Type: Review

References (88)

1. Howell, A. et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005
2. Thurlimann, B. et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005
3. Coombes, R. C. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004
4. Goss, P. E. et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97, 1262-1271 (2005
5. Eastell, R. et al. Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230. J. Clin. Oncol. 26, 1051-1057 (2008
6. Coleman, R. E. et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol. 8, 119-127 (2007
7. Shahinian, V. B., Kuo, Y. F., Freeman, J. L. & Goodwin, J. S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154-164 (2005
8. Smith, M. R. et al. Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with non-metastatic prostate cancer. J. Clin. Oncol. 23, 7897-7903 (2005
9. Kanis, J. A., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385-397 (2008
10. Melton, L. J., Chrischiles, E. A., Cooper, C., Lane, A. W. & Riggs, B. L. Perspective: How many women have osteoporosis? J. Bone Miner. Res. 7, 1005-1010 (1992
11. [No authors listed] Who are candidates for prevention and treatment for osteoporosis? Osteoporos. Int. 7, 1-6 (1997
12. Siris, E. S. et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment. JAMA 286, 2815-2822 (2001
13. Watts, N. B. et al. Osteoporosis in men: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 97, 1802-1822 (2012
14. Kanis, J. A. et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos. Int. 18, 1033-1046 (2007
15. Kanis, J. A., McCloskey, E., Johansson, H., Oden, A. & Leslie, W. D. FRAX with and without bone mineral density. Calcif. Tissue Int. 90, 1-13 (2012
16. Saurel, C. A., Patel, T. A. & Perez, E. A. Changes to adjuvant systemic therapy in breast cancer: A decade in review. Clin. Breast Cancer 10, 196-208 (2010
17. Hadji, P. et al. Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention? Cancer Treat. Rev. 38, 798-806 (2012
18. Vehmanen, L. et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur. J. Cancer 37, 2373-2378 (2001
19. Cameron, D., Douglas, S., Brown, J. & Anderson, R. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: Is it dependent on oestrogen deficiency? Breast Cancer Res. Treat. 123, 805-814 (2010
20. Shapiro, C. L., Manola, J. & Leboff, M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J. Clin. Oncol. 19, 3306-3311 (2001
21. Hadji, P., Ziller, M., Maskow, C., Albert, U. & Kalder, M. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur. J. Cancer 45, 3205-3212 (2009
22. Anderson, R. A. & Cameron, D. A. Pretreatment serum anti-Müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J. Clin. Endocrinol. Metab. 96, 1336-1343 (2011
23. Jonat, W. et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J. Clin. Oncol. 20, 4628-4635 (2002
24. Fogelman, I. et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos. Int. 14, 1001-1006 (2003
25. Gnant, M. F. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9, 840-849 (2008
26. O'Regan, R. M. & Jordan, V. C. The evolution of tamoxifen therapy in breast cancer: Selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 3, 207-214 (2002
27. Powles, T. J., Hickish, T., Kanis, J. A., Tidy, A. & Ashley, S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14, 78-84 (1996
28. Vehmanen, L., Elomaa, I., Blomqvist, C. & Saarto, T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J. Clin. Oncol. 24, 675-680 (2006
29. Fisher, B. et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 16, 1652-1662 (2005
30. Hadji, P. et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: Practical guidance for prevention and treatment. Ann. Oncol. 22, 2546-2555 (2011
31. Eastell, R. et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann. Oncol. 22, 857-862 (2011
32. Coleman, R. E. et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res. Treat. 124, 153-161 (2010
33. Peppone, L. J. et al. Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: A feasibility trial. Clin. Breast Cancer 10, 224-229 (2010
34. Winters-Stone, K. et al. Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: A randomized, controlled trial. Breast Cancer Res. Treat. 127, 447-456 (2011
35. Waltman, N. et al. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: A 24-month randomized controlled trial. Osteoporos. Int. 21, 1361-1369 (2010
36. Tang, B. M. P., Eslick, G. D., Nowson, C., Smith, C. & Bensoussan, A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. Lancet 370, 657-666 (2010
37. Bischoff-Ferrari, H. A. et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N. Engl. J. Med. 367, 40-44 (2012
38. Shao, T., Klein, P. & Grossbard, M. L. Vitamin D and breast cancer. Oncologist 17, 36-45 (2012
39. Coleman, R. E. et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-fast study): Final 60-month results. Ann. Oncol. 24, 398-405 (2013
40. Brufsky, A. et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol. 25, 829-836 (2007
41. Saarto, S. et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss which is reduced by clodronate: A randomised study in premenopausal patients. J. Clin. Oncol. 15, 1341-1347 (1997
42. van Poznak, C. et al. Prevention of aromatase inhibitor induced bone loss using risedronate: The SABRE trial. J. Clin. Oncol. 28, 967-973 (2010
43. Lester, J. E. et al. Prevention of anastozole induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res. 14, 6336-6342 (2008
44. Hines, S. L. et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J. Clin. Oncol. 27, 1047-1053 (2009
45. Hadji, P. et al. GRAND: The German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos. Int. 23, 223-231 (2012
46. Brown, J. E. & Coleman, R. E. Denosumab in patients with cancer - a surgical strike against the osteoclast. Nat. Rev. Clin. Oncol. 9, 110-118 (2012
47. Ellis, G. K. et al. Randomised trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J. Clin. Oncol. 26, 4875-4882 (2008
48. Ito, K., Blinder, V. S. & Elkin, E. B. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J. Clin. Oncol. 30, 1468-1475 (2012
49. Roehrborn, C. G. & Black, L. K. The economic burden of prostate cancer. BJU Int. 108, 806-813 (2011
50. Howlader, N. et al. (Eds) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD [online], http://seer.cancer.gov/csr/1975-2009-pops09 (2012
51. Labrie, F. Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat. Rev. Urol. 8, 73-85 (2011
52. LeBlanc, E. S. et al. The effects of serum testosterone, estradiol and sex hormone binding globulin levels on fracture risk in older men. J. Clin. Endocrinol. Metab. 94, 3337-3346 (2009
53. Novara, G. et al. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urol. Int. 82, 249-255 (2009
54. Brown, J. E., Sherriff, J. M. & James, N. D. Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: An increasing but under-recognized problem. BJU Int. 105, 1042-1043 (2010
55. Wadhwa, V. K., Weston, R., Mistry, R. & Parr, N. J. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 104, 800-805 (2009
56. Agarwal, M. M. et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 103, 2042-2052 (2005
57. Lee, C. E. et al. A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Curr. Oncol. 18, e163-e172 (2011
58. Planas, J. et al. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 99, 812-815 (2007
59. Datta, M. & Schwartz, G. G. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: A critical review. Oncologist 17, 1171-1179 (2012
60. Wang, L., Manson, J. E. & Sesso, H. D. Calcium intake and risk of cardiovascular disease: A review of prospective studies and randomized clinical trials. Am. J. Cardiovasc. Drugs 12, 105-116 (2012
61. Smith, M. R. et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345, 948-955 (2001
62. Smith. M. R. et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J. Urol. 169, 2008-2012 (2003
63. Michaelson, M. D. et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J. Clin. Oncol. 25, 1038-1042 (2007
64. Ryan, C. W., Huo, D., Demers, L. M., Beer, T. M. & Lacerna, L. V. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J. Urol. 176, 972-978 (2006
65. Greenspan, S. L. et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J. Clin. Oncol. 26, 4426-4434 (2008
66. Serpa Neto, A. et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 15, 36-44 (2012
67. Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745-755 (2009
68. Smith, M. R. et al. Tomerifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J. Urol. 184, 1316-1321 (2010
69. Smith, M. R. et al. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J. Urol. 186, 2239-2244 (2011
70. Abrahamsson, P. A. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature. Eur. Urol. 57, 49-59 (2010
71. Stockler, M. R. Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer. Ann. Intern. Med. 158, JC9 (2013
72. Yu, E. Y. et al. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with non-metastatic, hormone-sensitive prostate cancer. J. Clin. Oncol. 30, 1864-1870 (2012
73. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011
74. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1189 (2012
75. Reid, D. M. et al. Guidance for the management of breast cancer treatment induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treat. Rev. 34 (Suppl. 1), S3-S18 (2008
76. Lee, C. E. et al. A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Curr. Oncol. 18, e163-e172 (2011
77. Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009
78. Gnant, M. et al. Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12 [abstract]. J. Clin. Oncol. 29 (Suppl.), A520 (2011
79. Coleman, R. E. et al. Breast cancer adjuvant therapy with and without zoledronic acid. N. Engl. J. Med. 365, 1396-1405 (2011
80. Paterson, A. H. G. et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial. Lancet Oncol. 13, 734-742 (2012
81. Mobus, V. et al. GAIN (German Adjuvant Intergroup Node Positive) Study: A phase-III multicenter trial to compare dose dense, dose intense ETC (iddETC) vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer - 1st interim efficacy analysis [abstract]. Cancer Res. 71 (Suppl. 3), S2-S4 (2011
82. Smith, M. R. et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: Results of a global phase 3, randomised, placebo-controlled trial. Lancet 379, 39-46 (2012
83. Coleman, R. E., Gnant, M., Morgan, G. & Clezardin, P. Effects of bone-targeted agents on cancer progression and mortality. J. Natl Cancer Inst. 18, 1059-1067 (2012
84. WHO Collaborating Centre for Metabolic Bone Diseases. FRAX: WHO Fracture Risk Assessment Tool [online], http://www.sheffield.ac.uk/FRAX/ (2013
85. US National Library of Medicine. Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). ClinicalTrials.gov [online], http://clinicaltrials.gov/show/ NCT01077154 (2012
86. US National Library of Medicine. Study to determine treatment effects of denosumab in patients with breast cancer receiving aromatase inhibitor therapy. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00556374 (2013
87. FDA ODAC Briefing Document BLA 125320/28 Denosumab (Xgeva). February 8th 2012. [online], http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM290400.pdf.
88. Coleman, R. E. & Holen, I. Bone Metastases in Clinical Oncology 4th edn (eds Abeloff, M. D., Armitage, J. O., Niederhuber, J. E., Kastan, M. B. & McKenna, W. G.) (Elsevier, Churchill Livingstone, in press